Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 70 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Mantzoros, Christos S  [Clear All Filters]
Journal Article
Theocharidou, E., Giouleme O., Anastasiadis S., Markopoulou A., Pagourelias E., Vassiliadis T., et al. (2019).  Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis.. Dig Dis Sci. 64(6), 1686-1694.
Anastasilakis, A. D., Koulaxis D., Upadhyay J., Pagkalidou E., Kefala N., Perakakis N., et al. (2019).  Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls.. Horm Metab Res. 51(2), 112-119.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism. 96, iii-v.
Antoniadis, A. G., Petridou E. Th, Antonopoulos C. N., Dessypris N., Panagopoulou P., Chamberland J. P., et al. (2011).  Insulin resistance in relation to melanoma risk.. Melanoma Res. 21(6), 541-6.
Sahin-Efe, A., Polyzos S. A., Dincer F., Zaichenko L., McGovern R., Schneider B., et al. (2015).  Intracellular leptin signaling following effective weight loss.. Metabolism. 64(8), 888-95.
Polyzos, S. A., Kountouras J., Shields K., & Mantzoros C. S. (2013).  Irisin: a renaissance in metabolism?. Metabolism. 62(8), 1037-44.
Polyzos, S. A., Mathew H., & Mantzoros C. S. (2015).  Irisin: A true, circulating hormone.. Metabolism. 64(12), 1611-8.
Anastasilakis, A. D., Polyzos S. A., Makras P., Douni E., & Mantzoros C. S. (2019).  Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism. 93, 100-102.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018).  Irisin in metabolic diseases.. Endocrine. 59(2), 260-274.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Polyzos, S. A., Cundy T., & Mantzoros C. S. (2018).  Juvenile Paget disease.. Metabolism. 80, 15-26.
Dalamaga, M., Chou S. H., Shields K., Papageorgiou P., Polyzos S. A., & Mantzoros C. S. (2013).  Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives.. Cell Metab. 18(1), 29-42.
Polyzos, S. A., & Mantzoros C. S. (2015).  Leptin in health and disease: facts and expectations at its twentieth anniversary.. Metabolism. 64(1), 5-12.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2015).  Leptin in nonalcoholic fatty liver disease: a narrative review.. Metabolism. 64(1), 60-78.
Moon, H-S., Dalamaga M., Kim S-Y., Polyzos S. A., Hamnvik O-P., Magkos F., et al. (2013).  Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.. Endocr Rev. 34(3), 377-412.
Polyzos, S. A., & Mantzoros C. S. (2017).  Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications.. Metabolism. 72, A4-A10.
Kouvari, M., Valenzuela-Vallejo L., Guatibonza-Garcia V., Polyzos S. A., Deng Y., Kokkorakis M., et al. (2023).  Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.. Metabolism. 147, 155666.
Tessier, C. M., Polyzos S. A., Athyros V. G., & Mantzoros C. S. (2021).  Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism. 121, 154796.
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Polyzos, S. A., & Mantzoros C. S. (2014).  Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.. Metabolism. 63(2), 161-7.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Polyzos, S. A., Bugianesi E., Kountouras J., & Mantzoros C. S. (2017).  Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.. Metabolism. 66, 64-68.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.